🍽️ Amethopterin (R,S)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Cancer Treatment: Methotrexate is widely used in chemotherapy regimens for the treatment of various cancers, including leukemia, lymphoma, breast cancer, lung cancer, and others. It works by interfering with the synthesis of DNA and RNA, thereby inhibiting the growth and proliferation of cancer cells.

  2. Rheumatoid Arthritis: Methotrexate is a first-line treatment for rheumatoid arthritis (RA) and other inflammatory joint diseases. It helps reduce joint pain, swelling, and inflammation by suppressing the immune system and modulating the inflammatory response. Methotrexate is often used as a disease-modifying antirheumatic drug (DMARD) to slow down the progression of RA and prevent joint damage.

  3. Psoriasis and Other Skin Conditions: Methotrexate is effective in the treatment of severe psoriasis and other autoimmune skin conditions, such as psoriatic arthritis and dermatomyositis. It helps reduce skin inflammation, scaling, and plaque formation by inhibiting the rapid turnover of skin cells.

  4. Inflammatory Bowel Disease: Methotrexate is sometimes used off-label in the treatment of inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. It can help reduce intestinal inflammation and control disease activity in patients who do not respond adequately to other medications.

  5. Side Effects: Methotrexate can cause a range of side effects, which may vary depending on the dose, route of administration, and duration of treatment. Common side effects may include nausea, vomiting, diarrhea, mouth sores, fatigue, headache, hair loss, and skin rash. These side effects are usually mild and manageable but may require dose adjustments or supportive care.

  6. Bone Marrow Suppression: Methotrexate can suppress bone marrow function, leading to a decrease in the production of blood cells, including white blood cells, red blood cells, and platelets. This may increase the risk of infections, anemia, and bleeding, particularly at higher doses or with prolonged use.

  7. Hepatotoxicity: Methotrexate can cause liver toxicity, manifested by elevated liver enzymes and, rarely, liver failure. Patients taking methotrexate should undergo regular monitoring of liver function tests to detect and manage potential hepatotoxicity.

  8. Pulmonary Toxicity: Rarely, methotrexate can cause pulmonary toxicity, including interstitial pneumonitis and pulmonary fibrosis. Patients experiencing respiratory symptoms such as cough, dyspnea, or chest pain should seek medical attention promptly.

  9. Renal Toxicity: Long-term use of high-dose methotrexate may lead to renal toxicity, characterized by decreased kidney function and impaired urine concentration. Adequate hydration and urine alkalinization are often recommended to minimize the risk of renal toxicity during high-dose methotrexate therapy.

  10. Teratogenicity: Methotrexate is highly teratogenic and can cause birth defects or fetal death if taken during pregnancy. It is contraindicated in pregnant women and women of childbearing potential unless there are no suitable alternatives, and strict contraception measures are in place.

  11. Drug Interactions: Methotrexate may interact with other medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), certain antibiotics, and other immunosuppressive drugs. Close monitoring and dose adjustments may be necessary when methotrexate is used concomitantly with other medications.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of Amethopterin (R,S) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Lacticaseibacillus paracasei Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by Amethopterin (R,S)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Akkermansiaceae family Decreases 👪 Source Study
Dorea genus Decreases 👪 Source Study
Roseburia genus Decreases 👪 Source Study
Parabacteroides genus Decreases 👪 Source Study BMI, fat percent,blood pressure
Agathobacter genus Decreases 👪 Source Study
Bacteroides genus Decreases 👪 Source Study
Bifidobacterium genus Decreases 👪 Source Study
Collinsella genus Decreases 👪 Source Study proinflammatory
Coprococcus genus Decreases 👪 Source Study
Eggerthella genus Decreases 👪 Source Study
Lachnospira genus Decreases 👪 Source Study
Lacrimispora genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
Odoribacter genus Decreases 👪 Source Study
Phocaeicola genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Veillonella genus Decreases 👪 Source Study
Clostridium genus Decreases 👪 Source Study Pathogen
Akkermansia genus Decreases 📓 Source Study
Enterocloster genus Decreases 👪 Source Study
Blautia genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Clostridium perfringens A no rank Decreases 👶 Source Study
Clostridium perfringens C no rank Decreases 👶 Source Study
Clostridium perfringens CPE no rank Decreases 👶 Source Study
environmental samples no rank Decreases 👶 Source Study
unclassified Akkermansia no rank Decreases 👶 Source Study
Clostridium perfringens D no rank Decreases 👶 Source Study
Clostridium perfringens B no rank Decreases 👶 Source Study
Clostridium perfringens E no rank Decreases 👶 Source Study
Bacteroides xylanisolvens species Decreases 📓 Source Study
Odoribacter splanchnicus species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Agathobacter rectalis species Decreases 📓 Source Study
Bacteroides fragilis species Decreases 📓 Source Study H02076 Bacteroides infection
Bacteroides uniformis species Decreases 📓 Source Study Infectious bacteria
Bifidobacterium adolescentis species Decreases 📓 Source Study
Clostridium perfringens species Decreases 📓 Source Study Food poisoning, gas gangrene
Dorea formicigenerans species Decreases 📓 Source Study
Enterocloster bolteae species Decreases 📓 Source Study
Lacticaseibacillus paracasei species Decreases 📓 Source Study
Mediterraneibacter gnavus species Decreases 📓 Source Study
Phocaeicola vulgatus species Decreases 📓 Source Study
Roseburia hominis species Decreases 📓 Source Study
Roseburia intestinalis species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Thomasclavelia ramosa species Decreases 📓 Source Study
Veillonella parvula species Decreases 📓 Source Study
Collinsella aerofaciens species Decreases 📓 Source Study
Parabacteroides distasonis species Decreases 📓 Source Study
Blautia obeum species Decreases 📓 Source Study
Bacteroides caccae species Decreases 📓 Source Study
Akkermansia muciniphila species Decreases 📓 Source Study High Levels linked to long-lived individuals
Bifidobacterium longum species Decreases 📓 Source Study
Akkermansia massiliensis species Decreases 👶 Source Study
Candidatus Akkermansia intestinavium species Decreases 👶 Source Study
Eggerthella lenta species Decreases 📓 Source Study
Bacteroides ovatus species Decreases 📓 Source Study
Lachnospira eligens species Decreases 📓 Source Study
Coprococcus comes species Decreases 📓 Source Study
Akkermansia glycaniphila species Decreases 👶 Source Study
[Ruminococcus] torques species Decreases 📓 Source Study
Bifidobacterium longum subsp. longum subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. infantis subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suis subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases 👶 Source Study
Bifidobacterium longum subsp. suillum subspecies Decreases 👶 Source Study

Impact of Amethopterin (R,S) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Acne 0.6 0.3 1
ADHD 4.1 0.9 3.56
Age-Related Macular Degeneration and Glaucoma 1.1 0.4 1.75
Allergic Rhinitis (Hay Fever) 2.8 2.3 0.22
Allergies 5 2.2 1.27
Allergy to milk products 1.4 1 0.4
Alopecia (Hair Loss) 1.6 1.6
Alzheimer's disease 4.4 6 -0.36
Amyotrophic lateral sclerosis (ALS) Motor Neuron 2.7 0.4 5.75
Ankylosing spondylitis 3.2 1.2 1.67
Anorexia Nervosa 1.3 2.9 -1.23
Antiphospholipid syndrome (APS) 0.9 0.9
Asthma 5 2.9 0.72
Atherosclerosis 1.5 2.8 -0.87
Atrial fibrillation 3.8 1.6 1.37
Autism 8.1 7.8 0.04
Autoimmune Disease 0.6 1 -0.67
Barrett esophagus cancer 0.3 0.3 0
benign prostatic hyperplasia 0.3 -0.3
Biofilm 1.8 1.8
Bipolar Disorder 1.2 1.4 -0.17
Brain Trauma 0.9 1.1 -0.22
Cancer (General) 0.6 2.9 -3.83
Carcinoma 2.9 2.3 0.26
Celiac Disease 3 3.1 -0.03
Cerebral Palsy 1.5 1 0.5
Chronic Fatigue Syndrome 4 5.6 -0.4
Chronic Kidney Disease 3.2 2.2 0.45
Chronic Lyme 0.8 -0.8
Chronic Obstructive Pulmonary Disease (COPD) 2.1 1.7 0.24
Chronic Urticaria (Hives) 0.8 1 -0.25
Coagulation / Micro clot triggering bacteria 0.7 1 -0.43
Cognitive Function 3.2 1.6 1
Colorectal Cancer 6.5 2.2 1.95
Constipation 1.2 0.7 0.71
Coronary artery disease 1.5 3 -1
COVID-19 7.7 11 -0.43
Crohn's Disease 7.4 5.2 0.42
Cushing's Syndrome (hypercortisolism) 0.9 -0.9
cystic fibrosis 1.9 -1.9
deep vein thrombosis 1.8 1.1 0.64
Denture Wearers Oral Shifts 1.5 1.5
Depression 10.9 8.7 0.25
Dermatomyositis 0.3 0.3 0
Eczema 1.4 2.6 -0.86
Endometriosis 2.3 1.7 0.35
Eosinophilic Esophagitis 0.6 -0.6
Epilepsy 2.7 1.7 0.59
erectile dysfunction 1.7 0.3 4.67
Fibromyalgia 3.1 1.4 1.21
Functional constipation / chronic idiopathic constipation 4.6 3.2 0.44
gallstone disease (gsd) 2.8 1 1.8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.5 1 0.5
Generalized anxiety disorder 2.1 2.4 -0.14
giant cell arteritis 0.2 -0.2
Glioblastoma 0.3 -0.3
Gout 1.8 0.7 1.57
Graves' disease 1.6 3 -0.88
Gulf War Syndrome 0.9 1.5 -0.67
Halitosis 0.9 0.3 2
Hashimoto's thyroiditis 2.9 1.1 1.64
Heart Failure 2.1 1.8 0.17
hemorrhagic stroke 1 1
Hidradenitis Suppurativa 0.9 0.3 2
High Histamine/low DAO 1.3 0.3 3.33
hypercholesterolemia (High Cholesterol) 0.5 0.4 0.25
hyperglycemia 1.8 1.7 0.06
Hyperlipidemia (High Blood Fats) 0.8 0.3 1.67
hypersomnia 0.4 -0.4
hypertension (High Blood Pressure 3.2 4.5 -0.41
Hypothyroidism 0.2 1 -4
Hypoxia 2.6 0.3 7.67
IgA nephropathy (IgAN) 1.3 3.3 -1.54
Inflammatory Bowel Disease 7.2 8.1 -0.13
Insomnia 2.5 2.7 -0.08
Intelligence 1.4 1.4
Intracranial aneurysms 0.9 0.9 0
Irritable Bowel Syndrome 6 5.1 0.18
ischemic stroke 2.3 1.1 1.09
Liver Cirrhosis 6.8 3.9 0.74
Long COVID 6.2 5.9 0.05
Low bone mineral density 1.1 -1.1
Lung Cancer 0.4 1.1 -1.75
Mast Cell Issues / mastitis 0.3 0.6 -1
ME/CFS with IBS 1.1 1.7 -0.55
ME/CFS without IBS 1.7 2.3 -0.35
membranous nephropathy 0.3 0.3
Menopause 1.4 0.7 1
Metabolic Syndrome 6.3 7.9 -0.25
Mood Disorders 11.2 6.6 0.7
multiple chemical sensitivity [MCS] 1.4 0.1 13
Multiple Sclerosis 6.4 5.5 0.16
Multiple system atrophy (MSA) 1.8 0.4 3.5
myasthenia gravis 0.3 0.7 -1.33
neuropathic pain 0.3 3.4 -10.33
Neuropathy (all types) 0.9 2.2 -1.44
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3.6 4.7 -0.31
NonCeliac Gluten Sensitivity 1.7 0.6 1.83
Obesity 9.5 8.9 0.07
obsessive-compulsive disorder 4 3.4 0.18
Osteoarthritis 2.7 1.1 1.45
Osteoporosis 1.6 1.7 -0.06
pancreatic cancer 0.6 0.3 1
Parkinson's Disease 6.6 6.5 0.02
Polycystic ovary syndrome 5.3 2.2 1.41
Postural orthostatic tachycardia syndrome 0.2 0.6 -2
Premenstrual dysphoric disorder 0.7 0.4 0.75
primary biliary cholangitis 1.2 1.4 -0.17
Primary sclerosing cholangitis 2.7 2.7 0
Psoriasis 3.2 3.1 0.03
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 6 4.4 0.36
Rosacea 0.3 1 -2.33
Schizophrenia 6.5 2.9 1.24
scoliosis 0.3 0 0
Sjögren syndrome 2 3.2 -0.6
Sleep Apnea 1.6 1.5 0.07
Slow gastric motility / Gastroparesis 0.6 0.3 1
Small Intestinal Bacterial Overgrowth (SIBO) 1.4 0.3 3.67
Stress / posttraumatic stress disorder 2.5 2.8 -0.12
Systemic Lupus Erythematosus 3.7 2.2 0.68
Tic Disorder 1.2 1.2 0
Tourette syndrome 1.1 0.3 2.67
Type 1 Diabetes 3.2 3.8 -0.19
Type 2 Diabetes 7.8 7.3 0.07
Ulcerative colitis 5.2 5.4 -0.04
Unhealthy Ageing 4.4 2.6 0.69
Vitiligo 2.2 1.1 1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.
Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]

Due to AI drones slamming this site, we have added IP blocking on excessive calls. Email us if you get blocked and send this [216.73.216 ]